 ABL1 mutations have been found to be a genetic dependency in non-small cell lung cancer, NSCLC. These mutations cause an increase in downstream signaling pathways, leading to an increased cytosolic localization of the ABL1 kinase. This leads to increased sensitivity to ABL1 inhibitors, such as imatinib, making it possible to stratify NSCLC patients with ABL1 mutations for treatment with imatinib in combination with other therapies. This article was authored by Eulina Tastoni, Natalie L. Stevenson, Pedro Torres Iuso, and others.